Novartis AG
Use of IL-1 beta Binding Antibodies
Last updated:
Abstract:
The present invention relates to an IL-1.beta. binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
Status:
Application
Type:
Utility
Filling date:
9 Mar 2021
Issue date:
2 Dec 2021